What would you like to look for?
Site search

23 November 2021

Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. The purchase price is CHF 20m plus success-based clinical earn-out payments in the low triple-digit million range. Inositec’s novel asset INS-3001, is a once-daily subcutaneous treatment for patients with vascular calcification disorders PAD and AVS, which are both major contributors to cardiovascular morbidity and mortality in affected patient populations. Inositec was a Venture Kick winner in 2012, a Venture Leader in 2014, and one of the TOP 100 Swiss Startups from 2016 to 2019.

VISCHER has been advising Inositec since its foundation in 2015. The team at VISCHER is led by Dr. Matthias Staehelin (Partner) with Pauline Pfirter (Associate), Sebastian Flückiger (Senior Associate) and Luzius Zumstein (Senior Associate), all Corporate.

Categories: Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.